
<!DOCTYPE html>
<html>
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta http-equiv="X-UA-Compatible" content="ie=edge">
<title>Markmap</title>
<style>
* {
  margin: 0;
  padding: 0;
}
#mindmap {
  display: block;
  width: 100vw;
  height: 100vh;
}
</style>
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/style.css">
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.16.8/dist/katex.min.css">
</head>
<body>
<svg id="mindmap"></svg>
<script src="https://cdn.jsdelivr.net/npm/d3@7.8.5/dist/d3.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-view@0.17.0/dist/browser/index.js"></script>
<script src="https://cdn.jsdelivr.net/npm/markmap-toolbar@0.17.0/dist/index.js"></script>
<script>
window.WebFontConfig = {
  custom: {
    families: [
      "KaTeX_AMS","KaTeX_Caligraphic:n4,n7","KaTeX_Fraktur:n4,n7",
      "KaTeX_Main:n4,n7,i4,i7","KaTeX_Math:i4,i7","KaTeX_Script",
      "KaTeX_SansSerif:n4,n7,i4","KaTeX_Size1","KaTeX_Size2",
      "KaTeX_Size3","KaTeX_Size4","KaTeX_Typewriter"
    ],
    active: function() {
      window.markmap.refreshHook.call();
    }
  }
};
</script>
<script src="https://cdn.jsdelivr.net/npm/webfontloader@1.6.28/webfontloader.js" defer></script>
<script>
(() => {
  setTimeout(() => {
    const { markmap: Markmap, mm: markmapInstance } = window;
    const toolbar = new Markmap.Toolbar();
    toolbar.attach(markmapInstance);
    const toolbarElement = toolbar.render();
    toolbarElement.style.position = 'absolute';
    toolbarElement.style.bottom = '20px';
    toolbarElement.style.right = '20px';
    document.body.append(toolbarElement);
  });

  ((getMarkmap, getOptions, root, jsonOptions) => {
    const markmap = getMarkmap();
    window.mm = markmap.Markmap.create(
      "svg#mindmap",
      (getOptions || markmap.deriveOptions)(jsonOptions),
      root
    );
  })(() => window.markmap, null, {"content":"BCM Breast Cancer Trials","children":[{"content":"MED ONC","children":[{"content":"Adjuvant","children":[{"content":"HER2","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"4,5\"><strong>FLAMINGO -01</strong></p>","children":[{"content":"\n<p data-lines=\"6,7\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Stage I/II with nonpCR OR stage III (pCR or not) to be enorlled &lt;90 days from completion of HP/TDM1</p>","children":[],"payload":{"lines":"6,9"}},{"content":"\n<p data-lines=\"9,10\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TWO cohorst depending on HLA-A-02</p>","children":[],"payload":{"lines":"9,10"}}],"payload":{"lines":"4,10"}},{"content":"\n<p data-lines=\"10,11\"><strong>CompassHER2 RD</strong></p>","children":[{"content":"\n<p data-lines=\"12,13\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Prior NACT with 6 or more cycles of chemo (at least 9 weeks or THP). If was part of EA1181, must receive 2 more cycles of chemo</p>","children":[],"payload":{"lines":"12,15"}},{"content":"\n<p data-lines=\"15,16\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ must be ypN+ (1/2/3) with ypT1/2/3. Weak ER+ can be ypN0. Will be randomized to TDM1 vs TDM1 and Tucatinib. May receive ≤ 1 cycle adjuvant T-DM1 prior to registration</p>","children":[],"payload":{"lines":"15,16"}}],"payload":{"lines":"10,16"}},{"content":"\n<p data-lines=\"16,17\"><strong>CompassHER2 RD</strong></p>","children":[{"content":"\n<p data-lines=\"18,19\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Prior NACT with 6 or more cycles of chemo (at least 9 weeks or THP). If was part of EA1181, must receive 2 more cycles of chemo</p>","children":[],"payload":{"lines":"18,21"}},{"content":"\n<p data-lines=\"21,22\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER- can be ypT1/2/3 with ypN0/1/2/3. Will be randomized to TDM1 vs TDM1 and Tucatinib. May receive ≤ 1 cycle adjuvant T-DM1 prior to registration</p>","children":[],"payload":{"lines":"21,22"}}],"payload":{"lines":"16,22"}},{"content":"\n<p data-lines=\"22,23\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"24,25\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"24,27"}},{"content":"\n<p data-lines=\"27,28\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"27,28"}}],"payload":{"lines":"22,28"}},{"content":"\n<p data-lines=\"28,29\">FLEX</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"30,31"}}],"payload":{"lines":"28,31"}}],"payload":{"lines":"3,31"}}],"payload":{"lines":"2,31"}},{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"33,34\"><strong>CAMBRIA-1</strong></p>","children":[{"content":"\n<p data-lines=\"35,36\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Intermediate and High risk to randomize between adjuvant year 2 : 5 to either continue adj. ET SoC vs oral SERD</p>","children":[],"payload":{"lines":"35,38"}},{"content":"\n<p data-lines=\"38,39\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Intermediate: T3 N0 | T1c/T2 N1 [2-3 LN] | T1c/T2 N0 (Grade III, KI67 &gt;= 20%, LumB/RS26, or prior chemotherapy)</p>","children":[],"payload":{"lines":"38,41"}},{"content":"\n<p data-lines=\"41,42\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> High: Stage III | T1c/T2 N1 [2-3]  (Grade III, KI67 &gt;= 20%, LumB/RS26) | T1c/T2 N1 [1/3] (Grade III, KI67 &gt;= 20%, LumB/RS26)</p>","children":[],"payload":{"lines":"41,42"}}],"payload":{"lines":"33,42"}},{"content":"\n<p data-lines=\"42,43\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"44,45\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"44,47"}},{"content":"\n<p data-lines=\"47,48\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"47,48"}}],"payload":{"lines":"42,48"}},{"content":"\n<p data-lines=\"48,49\"><strong>OFSET (NRG BR009)</strong></p>","children":[{"content":"\n<p data-lines=\"50,51\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ (&gt;1%) HER2- with pT1-3 pN0-1.</p>","children":[],"payload":{"lines":"50,53"}},{"content":"\n<p data-lines=\"53,54\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> RS N1 &lt;26. RS N0 21-25. RS N0 16-20 WITH T minimum at 30mm (G1), 20mm (G2) or 10mm (G3)</p>","children":[],"payload":{"lines":"53,54"}}],"payload":{"lines":"48,54"}},{"content":"\n<p data-lines=\"54,55\">FLEX</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"56,57"}}],"payload":{"lines":"54,57"}}],"payload":{"lines":"32,57"}}],"payload":{"lines":"31,57"}},{"content":"TNBC","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"59,60\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"61,62\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"61,64"}},{"content":"\n<p data-lines=\"64,65\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"64,65"}}],"payload":{"lines":"59,65"}},{"content":"\n<p data-lines=\"65,66\"><strong>OptimICE-PCR</strong></p>","children":[{"content":"\n<p data-lines=\"67,68\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC (ER/PR &lt;10%)  T1cN1-2 or T2-4N0-2 with ypT0 OR ypTis</p>","children":[],"payload":{"lines":"67,70"}},{"content":"\n<p data-lines=\"70,71\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Adju RT  and Pembro, followed by registration</p>","children":[],"payload":{"lines":"70,71"}}],"payload":{"lines":"65,71"}},{"content":"\n<p data-lines=\"71,72\">ASCENT-05 (NASBP)</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC (&lt;10%) with residual disease","children":[],"payload":{"lines":"73,74"}}],"payload":{"lines":"71,74"}},{"content":"\n<p data-lines=\"74,75\">FLEX</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"76,77"}}],"payload":{"lines":"74,77"}}],"payload":{"lines":"58,77"}}],"payload":{"lines":"57,77"}}],"payload":{"lines":"1,77"}},{"content":"Metastatic","children":[{"content":"HER2","children":[{"content":"1","children":[{"content":"\n<p data-lines=\"80,81\"><strong>STOPHER2 / TBCRC 062</strong></p>","children":[{"content":"\n<p data-lines=\"82,83\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> On 1st Line ABC HER2+ for 3 or more years. If brain disease, has to be stable for 2 or more years</p>","children":[],"payload":{"lines":"82,85"}},{"content":"\n<p data-lines=\"85,86\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Continue ET therapy. Can be enrolled if ET was changed</p>","children":[],"payload":{"lines":"85,86"}}],"payload":{"lines":"80,86"}},{"content":"\n<p data-lines=\"86,87\"><strong>STOPHER2 / TBCRC 062</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> On 1st Line ABC HER2+ for 3 or more years. If brain disease, has to be stable for 2 or more years","children":[],"payload":{"lines":"88,89"}}],"payload":{"lines":"86,89"}}],"payload":{"lines":"79,89"}},{"content":"2","children":[{"content":"\n<p data-lines=\"90,91\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"92,93\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"92,95"}},{"content":"\n<p data-lines=\"95,96\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"95,96"}}],"payload":{"lines":"90,96"}}],"payload":{"lines":"89,96"}},{"content":"3","children":[{"content":"\n<p data-lines=\"97,98\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"99,100\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"99,102"}},{"content":"\n<p data-lines=\"102,103\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"102,103"}}],"payload":{"lines":"97,103"}}],"payload":{"lines":"96,103"}},{"content":"4","children":[{"content":"\n<p data-lines=\"104,105\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"106,107\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"106,109"}},{"content":"\n<p data-lines=\"109,110\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"109,110"}}],"payload":{"lines":"104,110"}}],"payload":{"lines":"103,110"}}],"payload":{"lines":"78,110"}},{"content":"HR POS","children":[{"content":"\n<p data-lines=\"111,112\">1</p>","children":[{"content":"\n<p data-lines=\"112,113\">EvoPAR-Breast01</p>","children":[{"content":"\n<p data-lines=\"114,115\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> DenoVo metastatic opr 1ry resistant ER+ (&gt;1%)</p>","children":[],"payload":{"lines":"114,117"}},{"content":"\n<p data-lines=\"117,118\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> BRCA1/2 OR PALB2 (either germline or somatic)</p>","children":[],"payload":{"lines":"117,118"}}],"payload":{"lines":"112,118"}},{"content":"\n<p data-lines=\"118,119\">TBCRC 064</p>","children":[],"payload":{"lines":"118,120"}}],"payload":{"lines":"111,120"}},{"content":"\n<p data-lines=\"120,121\">2</p>","children":[{"content":"\n<p data-lines=\"121,122\"><strong>ELAINE-III</strong></p>","children":[{"content":"\n<p data-lines=\"123,124\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Progression on 1st Line CDK4/6. ESR1 mutation</p>","children":[],"payload":{"lines":"123,126"}},{"content":"\n<p data-lines=\"126,127\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No priot Abema in adjuvant or metastatic setting</p>","children":[],"payload":{"lines":"126,127"}}],"payload":{"lines":"121,127"}},{"content":"\n<p data-lines=\"127,128\"><strong>OPERA-1</strong></p>","children":[{"content":"\n<p data-lines=\"129,130\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Post 1st Line progression while on ET/CDK , adjuvant ET or within 2 years post ET. No prior Chemo in Stage 4.</p>","children":[],"payload":{"lines":"129,132"}},{"content":"\n<p data-lines=\"132,133\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI]</p>","children":[],"payload":{"lines":"132,133"}}],"payload":{"lines":"127,133"}},{"content":"\n<p data-lines=\"133,134\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"135,136\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"135,138"}},{"content":"\n<p data-lines=\"138,139\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"138,139"}}],"payload":{"lines":"133,139"}},{"content":"\n<p data-lines=\"139,140\">TBCRC 064</p>","children":[],"payload":{"lines":"139,141"}}],"payload":{"lines":"120,141"}},{"content":"\n<p data-lines=\"141,142\">3</p>","children":[{"content":"\n<p data-lines=\"142,143\"><strong>OPERA-1</strong></p>","children":[{"content":"\n<p data-lines=\"144,145\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Post 2 Lines Line of ET, lasting at least 6 months. No prior Chemo in Stage 4.</p>","children":[],"payload":{"lines":"144,147"}},{"content":"\n<p data-lines=\"147,148\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Part A three arm for OP 120, OP 90 and SoC. Part B is OP vs SoC [Faslo or AI]</p>","children":[],"payload":{"lines":"147,150"}},{"content":"\n<p data-lines=\"150,151\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> If 2nd line was Faslo, 3rd line SoC can be AI</p>","children":[],"payload":{"lines":"150,151"}}],"payload":{"lines":"142,151"}},{"content":"\n<p data-lines=\"151,152\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"153,154\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"153,156"}},{"content":"\n<p data-lines=\"156,157\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"156,157"}}],"payload":{"lines":"151,157"}}],"payload":{"lines":"141,157"}},{"content":"\n<p data-lines=\"157,158\">4</p>","children":[{"content":"\n<p data-lines=\"158,159\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"160,161\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"160,163"}},{"content":"\n<p data-lines=\"163,164\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"163,164"}}],"payload":{"lines":"158,164"}}],"payload":{"lines":"157,164"}}],"payload":{"lines":"110,164"}},{"content":"TNBC","children":[{"content":"\n<p data-lines=\"165,166\">1</p>","children":[{"content":"\n<p data-lines=\"166,167\"><strong>TBCRC 061</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Receipt of Immunotherapy in the advanced setting","children":[],"payload":{"lines":"168,169"}}],"payload":{"lines":"166,169"}},{"content":"\n<p data-lines=\"169,170\">TBCRC 064</p>","children":[],"payload":{"lines":"169,171"}}],"payload":{"lines":"165,171"}},{"content":"\n<p data-lines=\"171,172\">2</p>","children":[{"content":"\n<p data-lines=\"172,173\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"174,175\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"174,177"}},{"content":"\n<p data-lines=\"177,178\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"177,178"}}],"payload":{"lines":"172,178"}},{"content":"\n<p data-lines=\"178,179\"><strong>TBCRC 061</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Receipt of Immunotherapy in the advanced setting","children":[],"payload":{"lines":"180,181"}}],"payload":{"lines":"178,181"}},{"content":"\n<p data-lines=\"181,182\">TBCRC 064</p>","children":[],"payload":{"lines":"181,183"}}],"payload":{"lines":"171,183"}},{"content":"\n<p data-lines=\"183,184\">3</p>","children":[{"content":"\n<p data-lines=\"184,185\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"186,187\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"186,189"}},{"content":"\n<p data-lines=\"189,190\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"189,190"}}],"payload":{"lines":"184,190"}},{"content":"\n<p data-lines=\"190,191\"><strong>TBCRC 061</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Receipt of Immunotherapy in the advanced setting","children":[],"payload":{"lines":"192,193"}}],"payload":{"lines":"190,193"}}],"payload":{"lines":"183,193"}},{"content":"\n<p data-lines=\"193,194\">4</p>","children":[{"content":"\n<p data-lines=\"194,195\"><strong>VISTA</strong></p>","children":[{"content":"\n<p data-lines=\"196,197\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> HER2 3+ OR 2+ by IHC via CB11 antibody (Leica) or anti HER2/neu (4B5) (VENTANA)</p>","children":[],"payload":{"lines":"196,199"}},{"content":"\n<p data-lines=\"199,200\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Meaurable disease with at least one site of injection. Can be 2nd line and after, with no limits on prior lines.</p>","children":[],"payload":{"lines":"199,200"}}],"payload":{"lines":"194,200"}}],"payload":{"lines":"193,200"}}],"payload":{"lines":"164,200"}}],"payload":{"lines":"77,200"}},{"content":"Neoadjuvant","children":[{"content":"HER2","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"203,204\"><strong>RESPONSE</strong></p>","children":[{"content":"\n<p data-lines=\"205,206\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers</p>","children":[],"payload":{"lines":"205,208"}},{"content":"\n<p data-lines=\"208,209\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Will receive weekly Taxol HP  with ddAC</p>","children":[],"payload":{"lines":"208,209"}}],"payload":{"lines":"203,209"}},{"content":"\n<p data-lines=\"209,210\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"211,212\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"211,214"}},{"content":"\n<p data-lines=\"214,215\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"214,215"}}],"payload":{"lines":"209,215"}},{"content":"\n<p data-lines=\"215,216\">FLEX</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"217,218"}}],"payload":{"lines":"215,218"}}],"payload":{"lines":"202,218"}}],"payload":{"lines":"201,218"}},{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"220,221\"><strong>RESPONSE</strong></p>","children":[{"content":"\n<p data-lines=\"222,223\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers</p>","children":[],"payload":{"lines":"222,225"}},{"content":"\n<p data-lines=\"225,226\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> High Risk ER+ (Grade III, Age &lt;50, ER &lt; 6/8 OR Ki67 &gt;29%). Will receive weekly Taxol with ddAC</p>","children":[],"payload":{"lines":"225,226"}}],"payload":{"lines":"220,226"}},{"content":"\n<p data-lines=\"226,227\">EVANGELINE</p>","children":[{"content":"\n<p data-lines=\"228,229\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Clinical T2 or T3 and N0 or N1 with Grade I and II</p>","children":[],"payload":{"lines":"228,231"}},{"content":"\n<p data-lines=\"231,232\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ER+ 67% or more, Allred 6-8</p>","children":[],"payload":{"lines":"231,232"}}],"payload":{"lines":"226,232"}},{"content":"\n<p data-lines=\"232,233\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"234,235\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"234,237"}},{"content":"\n<p data-lines=\"237,238\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"237,238"}}],"payload":{"lines":"232,238"}},{"content":"\n<p data-lines=\"238,239\">NCBRE</p>","children":[{"content":"\n<p data-lines=\"240,241\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> ILC ER+ PR+ HER2- with ERBB2 mutation.</p>","children":[],"payload":{"lines":"240,243"}},{"content":"\n<p data-lines=\"243,244\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1c (Min size 15mm) N0/N1/N2</p>","children":[],"payload":{"lines":"243,244"}}],"payload":{"lines":"238,244"}},{"content":"\n<p data-lines=\"244,245\"><strong>S2206</strong></p>","children":[{"content":"\n<p data-lines=\"246,247\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Stage II and III, including IBC. ER+ or PR+ per CAP (&gt;1%)</p>","children":[],"payload":{"lines":"246,249"}},{"content":"\n<p data-lines=\"249,250\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> High 2 on MP</p>","children":[],"payload":{"lines":"249,250"}}],"payload":{"lines":"244,250"}},{"content":"\n<p data-lines=\"250,251\"><strong>CDK4i PF0060</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3 POSTMENOpausal, with smallest size 15mm. Any N. Excludes T4 and N3","children":[],"payload":{"lines":"252,253"}}],"payload":{"lines":"250,253"}},{"content":"\n<p data-lines=\"253,254\">FLEX</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"255,256"}}],"payload":{"lines":"253,256"}}],"payload":{"lines":"219,256"}}],"payload":{"lines":"218,256"}},{"content":"TNBC","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"258,259\"><strong>RESPONSE</strong></p>","children":[{"content":"\n<p data-lines=\"260,261\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> 1ry 20mm or more (T2 N0 and higher) by exam or imaging. Excludes IBC and BL cancers</p>","children":[],"payload":{"lines":"260,263"}},{"content":"\n<p data-lines=\"263,264\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Will receive weekly Taxol with ddAC (Pembro added if indicated, Carbo added if T3)</p>","children":[],"payload":{"lines":"263,264"}}],"payload":{"lines":"258,264"}},{"content":"\n<p data-lines=\"264,265\"><strong>ICE COMPRESS / SWOG S2205</strong></p>","children":[{"content":"\n<p data-lines=\"266,267\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> NACT or Adjuvant Chemo with Taxanes (either weekly Taxol, Carbo Taxol or CarboTaxotere).</p>","children":[],"payload":{"lines":"266,269"}},{"content":"\n<p data-lines=\"269,270\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Not for Taxotere Cytoxan. Not for prior Taxane exposure. No pre-existing Neuropathy or Raynaud's</p>","children":[],"payload":{"lines":"269,270"}}],"payload":{"lines":"264,270"}},{"content":"\n<p data-lines=\"270,271\"><strong>S2212</strong></p>","children":[{"content":"\n<p data-lines=\"272,273\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> TNBC (ER/PR &lt;5%) with T2-T4 N0 OR T1-T3 N1-N2. Randomized to either KN522 versus Taxotere Carbo  Pembro x 6 Cycles</p>","children":[],"payload":{"lines":"272,275"}},{"content":"\n<p data-lines=\"275,276\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No Stage IIIC, IIIB T4 N+ OR IBC</p>","children":[],"payload":{"lines":"275,276"}}],"payload":{"lines":"270,276"}},{"content":"\n<p data-lines=\"276,277\">FLEX</p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> T1 to T3, with smallest size 6mm. Any N","children":[],"payload":{"lines":"278,279"}}],"payload":{"lines":"276,279"}}],"payload":{"lines":"257,279"}}],"payload":{"lines":"256,279"}}],"payload":{"lines":"200,279"}}],"payload":{"lines":"0,279"}},{"content":"RAD ONC","children":[{"content":"Adjuvant","children":[{"content":"HR POS","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"283,284\"><strong>MA39</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Newly Diagnosis of IDC w/ no metastisis<br>\nTreated with BCS or Mastectomy with no residual disease","children":[],"payload":{"lines":"285,287"}}],"payload":{"lines":"283,287"}}],"payload":{"lines":"282,287"}}],"payload":{"lines":"281,287"}}],"payload":{"lines":"280,287"}},{"content":"Postsurgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"290,291\">PREDICT II</p>","children":[{"content":"\n<p data-lines=\"292,293\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dx of DCIS w/ tumor size &lt;6cm</p>","children":[],"payload":{"lines":"292,295"}},{"content":"\n<p data-lines=\"295,296\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Eligible for BCS, radiation and/or systemic treatment</p>","children":[],"payload":{"lines":"295,296"}}],"payload":{"lines":"290,296"}}],"payload":{"lines":"289,296"}}],"payload":{"lines":"288,296"}}],"payload":{"lines":"287,296"}}],"payload":{"lines":"279,296"}},{"content":"SURG ONC","children":[{"content":"Peri-Surgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"300,301\"><strong>CHEST</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Undergoing Mastectomy + Reconstruction","children":[],"payload":{"lines":"302,303"}}],"payload":{"lines":"300,303"}},{"content":"\n<p data-lines=\"303,304\"><strong>Breast ATLAS</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Undergoing PPX Mastectomy","children":[],"payload":{"lines":"305,306"}}],"payload":{"lines":"303,306"}},{"content":"\n<p data-lines=\"306,307\"><strong>PRECISION</strong></p>","children":[{"content":"\n<p data-lines=\"308,309\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Dx of DCIS and/or IDC undergoing BCS or mastectomy</p>","children":[],"payload":{"lines":"308,311"}},{"content":"\n<p data-lines=\"311,312\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> No hx of prior therapy treatment</p>","children":[],"payload":{"lines":"311,312"}}],"payload":{"lines":"306,312"}},{"content":"\n<p data-lines=\"312,313\"><strong>SentiNot 2.0</strong></p>","children":[{"content":"\n<p data-lines=\"314,315\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Pre-operative diagnosis of DCIS or other suspicious lesion not confirmed to be invasive breast cancer</p>","children":[],"payload":{"lines":"314,317"}},{"content":"\n<p data-lines=\"317,318\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Willing to forgo initial SLNB and have SLNB as a later second procedure if DCIS is upgraded to invasive cancer</p>","children":[],"payload":{"lines":"317,318"}}],"payload":{"lines":"312,318"}},{"content":"\n<p data-lines=\"318,319\"><strong>Magellan</strong></p>","children":[{"content":"\n<p data-lines=\"320,321\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Non-metastatic patients with node positive breast cancer (cT0-4, N1)</p>","children":[],"payload":{"lines":"320,323"}},{"content":"\n<p data-lines=\"323,324\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Magseed placement prior to NAC</p>","children":[],"payload":{"lines":"323,324"}}],"payload":{"lines":"318,324"}}],"payload":{"lines":"299,324"}}],"payload":{"lines":"298,324"}}],"payload":{"lines":"297,324"}},{"content":"Presurgical","children":[{"content":"NO GROUP","children":[{"content":"NO LINE","children":[{"content":"\n<p data-lines=\"327,328\"><strong>ATUSA-iSONO</strong></p>","children":[{"content":"\n<p data-lines=\"329,330\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Women with a suspected breast lesion in one of both breasts</p>","children":[],"payload":{"lines":"329,332"}},{"content":"\n<p data-lines=\"332,333\"><svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Disease T1c or larger</p>","children":[],"payload":{"lines":"332,333"}}],"payload":{"lines":"327,333"}},{"content":"\n<p data-lines=\"333,334\"><strong>BCM TISSUE COLLECTION</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Suspicious lesion receiving an U/S guided biopsy with birads 4b-5","children":[],"payload":{"lines":"335,336"}}],"payload":{"lines":"333,336"}},{"content":"\n<p data-lines=\"336,337\"><strong>ANGEL</strong></p>","children":[{"content":"<svg width=\"16\" height=\"16\" viewBox=\"0 -3 24 24\"><path d=\"M19 3H5a2 2 0 0 0-2 2v14a2 2 0 0 0 2 2h14a2 2 0 0 0 2-2V5a2 2 0 0 0-2-2m-9 14-5-5 1.41-1.41L10 14.17l7.59-7.59L19 8z\"></path></svg> Any suspicious lesion receiving a biopsy","children":[],"payload":{"lines":"338,339"}}],"payload":{"lines":"336,339"}}],"payload":{"lines":"326,339"}}],"payload":{"lines":"325,339"}}],"payload":{"lines":"324,339"}}],"payload":{"lines":"296,339"}}],"payload":{"lines":"0,339"}}, {"initialExpandLevel":4,"maxWidth":250});
})();
</script>
</body>
</html>
